EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer

EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Bedminster, N.J., March 3, 2010 - EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing acute-care hospital products, today announced that its Executive Chairman John Bailye has been appointed Interim President and Chief Executive Officer replacing Howard Weisman who is no longer with the Company. Mr. Weisman will also no longer serve on EKR's Board of Directors.

About EKR Therapeutics
EKR Therapeutics is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes.  Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products. For additional information about EKR visit the Company's website at www.ekrtx.com.


Contact for EKR Therapeutics
Stuart Z. Levine, Ph.D.
Director, Strategic Communications
[email protected]

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.